Default company panoramic image
Final logo sm

QR Pharma, Inc.

QR Pharma is developing novel drugs to impede the progression of Alzheimer’s, Parkinson’s and other neurodegenerative disorders.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Berwyn, PA, US
  • Currency USD
  • Founded November 2008
  • Employees 3
  • Website qrpharma.com

Company Summary

The company is developing Posiphen® which inhibits the synthesis of toxic proteins involved in Alzheimer's and Parkinson's disease. Posiphen is distinct from other drugs in development, because due to its mechanism of action it is effective in a number of neurodegenerative disorders by protecting nerve cells from dying. Posiphen was found to be safe in animals and humans. In AD patients it normalized brain chemistry, making it a promising drug.

Team

  • 228871ef 3c48 4a08 8116 d673f0207c48
    President and CEO

    Founded QR Pharma to develop better therapeutics for neurodegenerative diseases. Was partner and director of Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; GM of Bachem Bioscience and Head Molecular Biology Mallinckrodt. Did a postdoc at Caltech and one at Roche Institute of Immunology. PhD in biochemistry is from The Rockefeller Univ.

  • Default avatar
    Eve Damiano, PhD
    VP Clinical

    Over 30 years experience in the Biotechnology, focused on matters relating to regulatory affairs, strategic planning and execution of development programs, including manufacturing, preclinical and clinical projects, writing and review of respective documentation for submission to FDA, and regulatory application review management in a wide range of therapeutic areas.

  • Default avatar
    Edward Cullen, PhD
    VP Regulatory

    Ph.D. in Biological Chemistry with over seventeen years of experience managing product development and regulatory submissions in the pharmaceutical industry. Experience includes writing and reviewing protocols; selecting and monitoring preclinical, analytical and clinical sites; writing and reviewing reports; preparing summaries, Investigators’ Brochures, INDs, NDAs, and worldwide regulatory submissions; and managing professional staff.

  • Default avatar
    Reid McCarthy
    CFO

    Senior level executive accomplished in successful early and commercial stage venture development, venture capital, private equity and bank financings, line operations, project and international finance. CFO of venture capital-backed
    development-stage pharmaceutical company and CEO of venture capital-backed agribusiness company.

  • Default avatar
    Michael Grundman, MD
    CMO

    Dr. Grundman is providing leadership for the clinical strategy and development at QR. Dr. Grundman currently is a Professor of Neurosciences at the University of California San Diego (UCSD) and previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy Research & Development, LLC and as Vice President of Clinical Development at Elan Pharmaceuticals.

  • Default avatar
    Michael Hoffman
    Chairman

    Mr. Hoffman is a Partner of Riverstone, where he is principally responsible for investments in power and renewable energy for Riverstone’s funds. Mr. Hoffman is co-head of Riverstone's Renewable Energy Funds I and II, with equity capital commitments of approximately $5 billion.

Advisors

  • Default avatar
    Duane Morris
    Lawyer
    Unconfirmed
    Default avatar
    EisnerAmper
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    BioAdvance (Biotechnology Greenhouse Corporation of Southeastern Pennsylvania)
    Unconfirmed
    Default avatar
    Ben Franklin Technology Partners
    Unconfirmed
    Default avatar
    Robin Hood Ventures and various Angel investors
    Unconfirmed